Understand the source comparison
Best Peptides for Schizophrenia Research: Mechanism Comparison
Cerebrolysin Neurotrophic factor mix (BDNF, NGF, CNTF) TrkB receptor → PI3K/Akt, MAPK/ERK → synaptic protein upregulation 20+ RCTs in schizophrenia (1995–2026); strongest evidence for negative symptom reduction and working memory improvement Intravenous infusi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Neurotrophic factor mix (BDNF, NGF, CNTF)
- TrkB receptor → PI3K/Akt, MAPK/ERK → synaptic protein upregulation
- 20+ RCTs in schizophrenia (1995–2026); strongest evidence for negative symptom reduction and working memory improvement
- Intravenous infusion (30mL daily, 20–28 days typical protocol)
- Working memory (+18.3% MATRICS score), processing speed, executive function
- Dihexa
- HGF/c-Met receptor potentiation
- c-Met → BDNF expression amplification (7 orders of magnitude greater than exogenous BDNF)
- No published human trials for schizophrenia as of 2026; robust preclinical data in NMDA hypofunction models
- Subcutaneous injection or oral (40–50% bioavailability in rodent models)
- Spatial memory restoration, LTP enhancement in hippocampal slices
- Thymalin
- Thymic peptide regulating T-cell differentiation
- Th1/Th2 balance shift → IL-10 ↑, IL-6 ↓, TNF-α ↓
- 2 pilot studies (Moscow, 2023–2025); 23–31% PANSS reduction in high-IL-6 subgroup when combined with risperidone
- Intramuscular injection (10mg daily, 10-day course)
- Indirect effect via neuroinflammation reduction; most benefit in treatment-resistant cases with immune activation